Hypertension – Current Treatment – Detailed, Expanded Analysis (US)
Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary artery disease, stroke, heart failure), renal failure, and death. Hypertension is treated with a large array of drugs, and guidelines emphasize the additive effects of using two or more drugs from different classes. Nevertheless, despite the numerous treatment options, significant unmet need remains in the treatment of resistant hypertension, which is defined as inadequately controlled BP despite the concurrent use of three or more antihypertensive agents. This report provides cardiologist insight into prescribing patterns for hypertension and especially resistant hypertension.
Questions Answered:
- What patient shares do angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) garner in the U.S. hypertension market? What are the trends in prescribing for resistant hypertension?
- How do physicians diagnose resistant hypertension, and how does this diagnosis influence their treatment approach?
- What factors constrain and what factors drive choice of hypertension treatment?
- What percentage of hypertensive patients receive monotherapy versus combination therapy?
Product Description:
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
GEOGRAPHY: United States
PRIMARY RESEARCH: Survey of 100 U.S. cardiologists
KEY DRUGS COVERED: ACE inhibitors, ARBs, diuretics, calcium channel blockers, beta blockers, aldosterone antagonists, mineralocorticoid receptor antagonists (MRAs), diuretics, direct renin inhibitors, centrally acting antihypertensives, and alpha blockers.
KEY INSIGHTS PROVIDED: Factors influencing disease management and treatment decisions; drivers of and constraints on treatment selection; physician-reported treatment practices; rationale for changes in treatment approach; physician insight on persistency and compliance; physician-reported recent/anticipated changes in treatment approach.
Dwaipayan Chatterjee, M.Pharm., Senior Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders analyst. Mr. Chatterjee authors reports on metabolic and cardiovascular indications. Previously, he was an equity analyst for the U.S. healthcare sector with Market Realist, where he worked on competitive intelligence and analysis of financial data. He was also a market research analyst for Mordor Intelligence, where he gained experience in market sizing, forecasting, and analyzing market dynamics. He holds a master’s degree with a specialization in pharmaceutical chemistry from the Birla Institute of Technology & Science in Pilani, India.